电邮这篇文章 Primenenie neselektivnogo antagonista retseptorov endotelina bozentana u bol'nykh idiopaticheskoy legochnoy gipertenziey: pervyy rossiyskiy opyt i vzglyad v budushchee
- 作者: Martynyuk TV1, Arkhipova OA1, Kobal' EA1, Eruslanova KA1, Danilov NM1, Chazova IE1
-
隶属关系:
- 期: 卷 8, 编号 4 (2011)
- 页面: 51-57
- 栏目: Articles
- URL: https://journals.eco-vector.com/2075-082X/article/view/33159
- DOI: https://doi.org/10.26442/SG33159
- ID: 33159
如何引用文章
全文:
详细
参考
- Национальные рекомендации ВНОК по диагностике и лечению легочной гипертензии. 2007.
- Guidelines for the diagnosis and treatment of pulmonary hypertension. The task force for the diagnosis and treatment of pulmonary hypertension of the ECS and ERS, endorsed by the ISHLT. Eur Heart J 2009; 30: 2493-537.
- Galie N, Manes A, Branzi A. The endothelin system in pulmonary hypertension. Cardiovasc Res 2004; 61: 227-37.
- McLaughlin VV, Sitbon O, Rubin L et al. The effect of first-line Bosentan on survival of patients with primary pulmonary hypertension. Am J Respir Crit Care Med 2003; 167: A442.
- Dupuis J, Hoeper MM. Endothelin receptor antagonists in pulmonary arterial hypertension. Eur Respir J 2008; 31: 407-15.
- Rubin LJ, Galie N, Badesch DB et al. Ambrisentan improves exercise capacity and clinical measures in pulmonary arterial hypertension. Am J Crit Care Med 2004; 169: A210.
- Rubin LJ, Badesch DB, Barst RJ et al. Bosentan therapy for pulmonary arterial hypertension. N Engl. J Med 2002; 346: 896-903.
- Galie N, Rubin LJ, Hoeper MM et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008; 371: 2093-100.
- Sitbon O, Badesch DB, Channick RN. Effects of the dual endothelin- receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest 2003; 124: 247-54.
- Provencher S et al. Long-term Outcome with First-line Bosentan Therapy in Idiopathic Pulmonary Arterial Hypertension. Eur Heart J 2006; 27: 589-95.
补充文件
